JACE HEBERT: Open Payments
NPI 1730533761 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$830 in 38 payments from 8 companies in 2025. Trend: 2023 $957 · 2024 $722 · 2025 $830
Food & beverage: $830
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $264 |
| Janssen Pharmaceuticals, Inc | 5 | $195 |
| E.R. Squibb & Sons, L.L.C. | 8 | $156 |
| Vanda Pharmaceuticals Inc. | 2 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: ARISTADA, INVEGA SUSTENNA, COBENFY, FANAPT, UZEDY, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE, CAPLYTA.
Industry payments across LA — which companies pay providers there.
